Glenmark Pharmaceuticals Ltd, through its wholly owned subsidiary Glenmark Specialty S.A., has advanced the Phase 3 clinical development of Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate (ADC), for the treatment of platinum-resistant ovarian cancer (PROC). India will become the first country across Glenmark’s licensed markets to initiate patient enrolment for the global Phase 3 clinical trial […]